Status:

UNKNOWN

Role of DcR3 in T Cell Activation in SLE and RA

Lead Sponsor:

National Taiwan University Hospital

Conditions:

SLE

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Brief Summary

Decoy receptor 3 (DcR3), a new member of tumor necrosis factor receptor (TNFR) superfamily, is a decoy receptor for FasL and could inhibit FasL-induced apoptosis, has recently been shown to induce cos...

Detailed Description

Specific Aim 1. Study DcR3-induced T cell activation in SLE and RA. A. Patients and controls Patients with SLE and RA in Department of Internal Medicine, National Taiwan University Hospital will be st...

Eligibility Criteria

Inclusion

  • SLE, RA

Exclusion

  • nil

Key Trial Info

Start Date :

January 1 2006

Trial Type :

OBSERVATIONAL

End Date :

December 1 2007

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT00275899

Start Date

January 1 2006

End Date

December 1 2007

Last Update

January 12 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Taiwan University Hospital

Taipei, Taiwan

Role of DcR3 in T Cell Activation in SLE and RA | DecenTrialz